News and Announcements
Novapep’s Pioneering Approach to Treating Inflammatory Bowel Diseases
- Published October 15, 2024 7:42AM UTC
- Publisher Maan Perez
- Categories Executive Interviews
Join Jay Hennock, CEO of Novapep, as he unveils the company’s mission to address unmet medical needs through peptide-based therapies.
Novapep, an Australian/US biotech, has developed a patented peptide structure called biparediteTM as an oral inflammatory bowel disease therapy, which will be a cost effective first-in-class drug. Biparetide has been shown in animals to be as effective as expensive, injectable biologic drugs (a US$20 billion market) and superior to corticosteroids, but with minimal expected side effects.
This video provides a compelling overview of their research and development efforts, focusing on inflammatory skin disorders, bowel disease, and sepsis, and their impact on global health.
Executive Interviews
The A$20.4 Million Inertia Trap: How Kepa Software Is Unlocking Value in Enterprise Capital Allocation
A government agency renewed the same maintenance decision nine years running, because auditing the original choice was deemed too expensive. When the portfolio was finally tested, A$20.4 million of low value spend was identified in a single year. Kepa Software’s capital governance platform was built to expose and eliminate precisely these boardroom blind spots. For […]
Forget the share price. SpaceX just published a map of the next five years.
Most coverage of SpaceX’s result focused on a 9.1% share price fall. That is noise. The signal is in the transcript: compute, power, bandwidth and demand over the next five years.
The prefab company that deliberately leaves part of the house unbuilt
BuiltQuik prefabricates the floor and roof structure and stops there. Co-founder Ryan Mullaney argues the omission is the product. Prefabricated housing usually means a factory. A large central facility, identical modules, limited room to move on design, and a logistics problem getting the finished box to site. BuiltQuik builds the opposite, and the design decision […]
Backed By Leading Investment Groups and Family Offices
